Product Portfolio header Spectrum Pharmaceuticals Product Portfolio picture
   
Oncology, Generics, Neurology Drugs About Spectrum Pharmaceuticals SPPI Investor Relations SPPI News
shadow area

Lucanthone - Phase 1

Thiaxanthenone

Target Indications
  • Malignant Brain Tumors

Route of Administration
  • Oral

Lucanthone Mode of Action
  • Lucanthone inhibits Topoisomerase II and interferes with the repair of DNA damage that is caused by radiation and chemotherapy
  • Specificity of lucanthone in combination with radiation or chemotherapy for the treatment of brain tumors arises from the fact that lucanthone acts preferentially on cycling cells (most of the normal brain cells are non-cycling) and the fact that lucanthone crosses the blood brain barrier efficiently
Lucanthone

Lucanthone Status
  • Phase 1 dose-escalation study in patients with recurrent malignant gliomas receiving temozolomide
Drug Properties
  • Oral Administration
  • Crosses the blood-brain barrier
  • Good safety given alone or with radiation therapy

All contents © Copyright Spectrum Pharmaceuticals, Inc. 2012. All Rights Reserved.  Terms of Use